CLAIMS OF THE APPLICATION:

1. (Currently amended) ~~An amorphous form of~~ Amorphous levocetirizine dihydrochloride.

2. (Currently amended) ~~An amorphous form of~~ Amorphous levocetirizine dihydrochloride, which is substantially free of crystalline forms of cetirizine dihydrochloride.

3. (Currently amended) ~~An amorphous form of~~ Amorphous levocetirizine dihydrochloride characterized by an X-ray powder diffraction pattern substantially in accordance with Figure (1).

4. (Currently amended) A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of ~~an~~ amorphous ~~form of~~ levocetirizine dihydrochloride and one or more pharmaceutically acceptable excipients.

5. (Original) The pharmaceutical composition of claim 4, which is substantially free of crystalline forms of cetirizine dihydrochloride.

6. (Original) A composition comprising levocetirizine dihydrochloride as a solid, wherein at least 80% by weight of said levocetirizine dihydrochloride is in an amorphous form.

7. (Currently amended) The composition of claim ~~5~~ 6, wherein at least 90% of said solid levocetirizine dihydrochloride is in an amorphous form.

8. (Original) The composition of claim 6, wherein at least 95% of said solid levocetirizine dihydrochloride is in an amorphous form.

9. (Currently amended) The composition of claim ~~7~~ 6, wherein at least 99% of said solid levocetirizine dihydrochloride is in an amorphous form.

10. (Currently amended) The composition of claim ~~8~~ 6, which is substantially free of crystalline forms of cetirizine dihydrochloride.

11. (Original) The composition of claim 6, wherein at least 1% of said solid levocetirizine dihydrochloride is in a crystalline form.

12. (Currently amended) The composition of claim ~~11~~ 6, wherein at least 5% of said solid levocetirizine dihydrochloride is in a crystalline form.

13. (Original) The composition of claim 6, which is a pharmaceutical composition.

14. (Original) The composition of claim 13, further comprising one or more pharmaceutically acceptable excipients.

15. (Currently amended) The composition of claim ~~14~~ 13, wherein said pharmaceutical composition is a solid dosage form for oral administration.

16. (Original) The composition of claim 15, wherein said solid dosage form is a tablet.

17. (Currently amended) The composition of claim 6 having a moisture content ranging from about 0.3% to about 12% by the KF method.

18. (Currently amended) The composition of claim 6 having a moisture content ranging from about 1.5% to about 7.5% by the KF method.

19. (Currently amended) A process for the preparation of ~~an~~ amorphous ~~form of (-) [2-[4-[(4-Chlorophenyl) phenyl methyl]-1-piperazinyl]ethoxy] acetic acid dihydrochloride (~~levocetirizine dihydrochloride~~), which comprises

a) providing levocetirizine free base or salt thereof in a solvent carrier;

b) treating said levocetirizine in said carrier with hydrochloric acid to form a dihydrochloride salt of cetirizine in solution;

c) removing said solvent carrier to obtain a residue;

d) adding a liquid hydrocarbon compound to said residue ~~thereby~~ to separate said amorphous ~~form of~~ levocetirizine dihydrochloride ~~separates~~ as a solid mass.

20. (Original) The process of claim 19, further comprising isolating said solid mass.

21. (Currently amended) The process of claim 20, further comprising removing ~~any~~ unbound solvent from said isolated solid mass to obtain a substantially dry form of said amorphous ~~form of~~ levocetirizine dihydrochloride.

22. (Original) The process of claim 21, wherein said step of removing said unbound solvent comprises drying said solid mass at a temperature of from about 60 to about 110 degrees Celsius.

23. Canceled.

24. (Currently amended) The process of claim 19, wherein said liquid hydrocarbon compound is selected from [[a]] the group consisting of toluene, xylene, cyclohexane, ~~or~~ and heptane.

25. (Currently amended) The process of claim 19, wherein said solvent carrier is selected from [[a]] the group consisting of a ketone solvent, an aqueous mixture of water miscible solvents, a nitrile solvent, ~~or~~ and a hydrocarbon solvent.

26. (Currently amended) The process of claim 25, wherein said ketone solvent is selected from [[a]] the group consisting of acetone, methyl ethyl ketone, ~~or~~ 2-pentanone, ~~or~~ and a mixture thereof.

27. (Currently amended) The process of claim 25, wherein said aqueous mixture of water miscible solvents ~~is~~ comprises a C_1-C_5 straight or branched chain alcoholic solvent.

28. (Currently amended) The process of claim 27, wherein the straight or branched chain alcoholic solvent is selected from the group consisting of methanol, ethanol, n-propanol, isopropanol, 2-butanol, n-butanol, n-pentanol ~~or~~ and 2-pentanol.

29. (Original) The process of claim 25, wherein said nitrile solvent is acetonitrile or propionitrile.

30. (Currently amended) The amorphous ~~form of~~ levocetirizine dihydrochloride produced in accordance with [[a]] the process of claim 19.

31. (Currently amended) The amorphous ~~form of~~ levocetirizine dihydrochloride produced in accordance with [[a]] the process of claim 22.

32. (Currently amended) The amorphous ~~form of~~ levocetirizine dihydrochloride produced in accordance with [[a]] the process of claim 25.

33. (Currently amended) A pharmaceutical composition comprising i) a prophylactically or therapeutically effective amount of amorphous levocetirizine dihydrochloride in a solid form produced by the process of claim 19, and ii) one or more pharmaceutically acceptable excipients.

34. (Original) The composition of claim 33, wherein said pharmaceutical composition is a solid dosage form for oral administration.

35. (Original) The composition of claim 34, wherein said solid dosage form is a tablet.

36. (Currently amended) The composition of claim 33, having a moisture content ranging from about 0.3% to about 12% by the KF method.

37. (Currently amended) The composition of claim 33, having a moisture content ranging from about 1.5% to about 7.5% by the KF method.